

## Special Issue

# Drug Safety and Risk Management in Clinical Practice

### Message from the Guest Editor

Safety monitoring of drugs throughout their whole life cycle is of paramount importance in order to protect public health and fulfill the whole scope of pharmacovigilance. Nevertheless, some adverse effects might not become apparent until after these products have been used for an extended period of time and by a large and diverse population, including those with concurrent illnesses and medications. Therefore, drug safety surveillance through spontaneous reporting systems (SRS) and post-authorization safety studies (PASS) using real-world data will provide information and new insights into the safety profiles of the drugs. This Special Issue welcomes reviews and original papers related to drug safety, such as, but not limited to, studies using active or passive methods for drug/vaccine monitoring (PASS, analysis of data from SRS, including signal detection/disproportionality analysis), studies on risks in special populations, and studies on risk minimization measures, including evaluations of the effectiveness of risk minimization measures.

### Guest Editor

Dr. Andreea Maria Farcas

Pharmacovigilance Research Center, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania

### Deadline for manuscript submissions

25 September 2025



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/199693](https://mdpi.com/si/199693)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)